However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...

Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive ...

Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...